In China a combination of IFN-I is being administered with lopinavir/ritonavir, ribavirin or remdesivir, which could increase the efficiency of treatment against COVID-19.119 In a recent study with recombinant human interferons (IFNα/β) conducted in Vero cells infected with SARS-CoV-2, it has been reported that it reduces the viral titers significantly.133 This means that an exogenous treatment with IFN-β actually further enhances the interferon-mediated antiviral response, which helps in a speedy recovery. The gene discussed is IFNA2; the disease is COVID-19.